Neptune Technologies & Bioressources Company Profile (CVE:NTB)

About Neptune Technologies & Bioressources (CVE:NTB)

Neptune Technologies & Bioressources logoNeptune Technologies & Bioressources Inc. (Neptune) is a biotechnology company. The Company is engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids (PUFAs). The Company operates in three segments: Neptune, Acasti Pharma Inc. and Acasti Pharma Inc. Its Neptune produces and commercializes nutraceutical products. Its Acasti Pharma Inc. develops and commercializes pharmaceutical applications for cardiovascular diseases. Its NeuroBioPharm Inc. develops and commercializes pharmaceutical applications for neurological diseases. It produces omega-3 PUFAs through its patented process of extracting oils from Antartic krill, which omega-3 PUFAs are then principally sold as bulk oil to Neptune's distributors who commercialize them under their private label primarily in the United States, European and Australian nutraceutical markets. The Company's products include Neptune Krill Oil (NKO) and ECOKRILL Oil (EKO).

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: CVE:NTB
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: C$116.92 million
  • Outstanding Shares: 77,945,000
Average Prices:
  • 50 Day Moving Avg: C$1.53
  • 200 Day Moving Avg: C$1.40
  • 52 Week Range: C$77,945,000.00 - C$1.08
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
 

Frequently Asked Questions for Neptune Technologies & Bioressources (CVE:NTB)

What is Neptune Technologies & Bioressources' stock symbol?

Neptune Technologies & Bioressources trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NTB."

How were Neptune Technologies & Bioressources' earnings last quarter?

Neptune Technologies & Bioressources Inc (CVE:NTB) released its quarterly earnings results on Tuesday, July, 15th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. The firm had revenue of $3.69 million for the quarter, compared to analysts' expectations of $7.31 million. View Neptune Technologies & Bioressources' Earnings History.

Who are some of Neptune Technologies & Bioressources' key competitors?

How do I buy Neptune Technologies & Bioressources stock?

Shares of Neptune Technologies & Bioressources and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How much does a share of Neptune Technologies & Bioressources stock cost?

One share of Neptune Technologies & Bioressources stock can currently be purchased for approximately C$1.50.

Analyst Ratings

Consensus Ratings for Neptune Technologies & Bioressources (CVE:NTB) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Neptune Technologies & Bioressources (CVE:NTB)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Neptune Technologies & Bioressources (CVE:NTB)
Earnings by Quarter for Neptune Technologies & Bioressources (CVE:NTB)
Earnings History by Quarter for Neptune Technologies & Bioressources (CVE:NTB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/15/2014($0.08)($0.06)$7.31 million$3.69 millionViewN/AView Earnings Details
5/21/2014($0.08)($0.08)$6.36 million$3.67 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Neptune Technologies & Bioressources (CVE:NTB)
Current Year EPS Consensus Estimate: $0.02 EPS

Dividends

Dividend History for Neptune Technologies & Bioressources (CVE:NTB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Neptune Technologies & Bioressources (CVE:NTB)
Insider Trades by Quarter for Neptune Technologies & Bioressources (CVE:NTB)
Insider Trades by Quarter for Neptune Technologies & Bioressources (CVE:NTB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/1/2016James Stuart HamiltonDirectorBuy4,000C$1.58C$6,320.00
1/28/2016James Stuart HamiltonDirectorBuy2,000C$1.55C$3,100.00
1/18/2016Mario ParadisInsiderBuy10,000C$1.50C$15,000.00
1/15/2016John Morris MoretzDirectorBuy700,651C$1.05C$735,683.55
1/15/2016Mario ParadisInsiderBuy40,000C$1.54C$61,672.00
10/29/2015John Morris MoretzDirectorBuy26,044C$1.08C$28,101.48
10/28/2015John Morris MoretzDirectorBuy24,500C$1.12C$27,538.00
10/27/2015John Morris MoretzDirectorBuy5,500C$1.09C$6,006.00
10/23/2015John Morris MoretzDirectorBuy50,000C$1.17C$58,385.00
10/5/2015John Morris MoretzDirectorBuy13,692C$1.24C$16,991.77
10/2/2015John Morris MoretzDirectorBuy33,900C$1.23C$41,663.10
9/15/2015John Morris MoretzDirectorBuy9,001C$1.24C$11,161.24
7/22/2015John Morris MoretzDirectorBuy2,800C$1.34C$3,750.60
7/21/2015John Morris MoretzDirectorBuy21,654C$1.34C$28,975.22
7/16/2015Pierre LemieuxDirectorSell6,250C$1.62C$10,135.00
6/8/2015Pierre FitzgibbonDirectorBuy47,500C$1.70C$80,693.00
2/17/2015Reed TucksonDirectorBuy10,800C$1.85C$19,931.40
2/13/2015Michel TimperioInsiderSell10,000C$2.19C$21,870.00
2/6/2015André GodinInsiderSell5,000C$2.14C$10,700.00
2/5/2015Michel TimperioInsiderSell15,000C$2.11C$31,680.00
1/30/2015Bel Dominique LeInsiderSell15,000C$2.30C$34,500.00
1/29/2015Bel Dominique LeInsiderSell10,000C$2.25C$22,500.00
1/22/2015Claudie LauzonInsiderSell8,334C$2.04C$16,966.36
1/22/2015Pierre LemieuxDirectorSell11,250C$2.00C$22,500.00
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Neptune Technologies & Bioressources (CVE:NTB)
Latest Headlines for Neptune Technologies & Bioressources (CVE:NTB)
Source:

Social

Chart

Neptune Technologies & Bioressources (NTB) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff